Evidence map›Paper›PMID 41263938›Full record

ArticleBriefings in bioinformatics2025

Accelerate the discovery of genetic variants in mitochondrial diseases with Variant prIOritization using Latent spAce.

Justine Labory, Youssef Boulaimen, Jasmine Singh, Samira Ait-El-Mkadem Saadi, Véronique Paquis-Flucklinger, Sylvie Bannwarth, Silvia Bottini

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Justine LaboryUniversité Côte d'Azur, Inserm U1081, CNRS UMR 7284, Institute for Research on Cancer and Aging Nice (IRCAN), 28, Ave de Valombrose, 06107 Nice Cedex 02, France.
Youssef BoulaimenHouse of modeling, simulations and interactions, Université Côte d'Azur, Parc Valrose - 28, avenue Valrose Nice Cedex 2 06108, France.
Jasmine SinghHouse of modeling, simulations and interactions, Université Côte d'Azur, Parc Valrose - 28, avenue Valrose Nice Cedex 2 06108, France.
Samira Ait-El-Mkadem SaadiUniversité Côte d'Azur, Inserm U1081, CNRS UMR 7284, Institute for Research on Cancer and Aging Nice (IRCAN), 28, Ave de Valombrose, 06107 Nice Cedex 02, France.
Véronique Paquis-FlucklingerUniversité Côte d'Azur, Inserm U1081, CNRS UMR 7284, Institute for Research on Cancer and Aging Nice (IRCAN), 28, Ave de Valombrose, 06107 Nice Cedex 02, France.
Sylvie BannwarthUniversité Côte d'Azur, Inserm U1081, CNRS UMR 7284, Institute for Research on Cancer and Aging Nice (IRCAN), 28, Ave de Valombrose, 06107 Nice Cedex 02, France.
Silvia BottiniINRAE, Université Côte d'Azur CNRS, Institut Sophia Agrobiotech, 400 route des chappes, BP 167 06903 Sophia Antipolis Cedex, France.ORCID 0000-0002-0605-4646

Funding

Agence Nationale pour la Recherche ANR 21-PMRB-0006French Foundation For Rare DiseaseNational Research Agency ANR-15-IDEX-01
6 · The paper itself

Abstract

Interpreting variants from whole-exome sequencing remains a major challenge, particularly for heterogeneous disorders such as mitochondrial diseases (MDs). To address this, we have developed Variant prIoritizatiOn using Latent spAce (VIOLA), a pipeline designed to help find a diagnosis for complex cases. VIOLA uses a variational autoencoder to embed functional annotations into a low-dimensional space, followed by DBSCAN-based outlier detection to identify potential pathogenic variants. Filtering steps and phenotype integration via HPO terms are then applied. The VIOLA score (Vscore) combines variant outlierness, transcriptomic co-expression data, and MD-specific annotations. Two rankings are derived: the VIOLA rank (all variants) and the ARrank (variants compatible with autosomal recessive inheritance). The VIOLA Aggregated score (VAscore) merges Vscore with Exomiser's pathogenicity score. Applied to 20 patients (four diagnosed), VIOLA reduced the variant list by >99% and ranked causal variants within the top 5 using ARrank, outperforming existing methods. Overall, VIOLA is a patient-specific strategy for variant prioritization, helping to resolve challenging MD cases and uncover novel disease mechanisms.

Indexed as

Genetic VariationMitochondrial DiseasesComputational BiologyExome SequencingHumansPhenotypeexome sequencingmachine learningmitochondrial diseasesmulti-omicsvariant prioritization

Identifiers

PMID41263938
PMCPMC12632193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.